Opinion|Videos|November 4, 2024
Patient Referrals of Bispecifics and Collaborative Efforts with Community Centers
Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or step-up dosing, returning patients to community practices for maintenance dosing, and managing grade 3/4 adverse events related to cytokine release syndrome or neurotoxicity.
Video content above is prompted by the following:
- How do you work with community oncology centers when receiving a patient referral for the initial/step-up dosing?
- What is the process for returning the patient to the community oncology practice for continued maintenance dosing?
If the patient develops grade 3/4 AEs associated with cytokine release syndrome or neurotoxicity, are they usually managed in the community or referred to your academic center?
